midazolam has been researched along with Hypopharyngeal Cancer in 1 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dou, YL | 1 |
| Lin, JP | 1 |
| Liu, FE | 1 |
| Wang, LY | 1 |
| Shu, HH | 1 |
| Jiang, N | 1 |
| Xie, Y | 1 |
| Duan, Q | 1 |
1 other study available for midazolam and Hypopharyngeal Cancer
| Article | Year |
|---|---|
Midazolam inhibits the proliferation of human head and neck squamous carcinoma cells by downregulating p300 expression.
Topics: Carcinoma, Squamous Cell; Cell Proliferation; Down-Regulation; E1A-Associated p300 Protein; Head and | 2014 |